Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian journal of psychiatry 2018-11, Vol.63 (11), p.730-739
Hauptverfasser: Martino, Davide, Karnik, Vikram, Osland, Sydney, Barnes, Thomas R. E., Pringsheim, Tamara M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 739
container_issue 11
container_start_page 730
container_title Canadian journal of psychiatry
container_volume 63
creator Martino, Davide
Karnik, Vikram
Osland, Sydney
Barnes, Thomas R. E.
Pringsheim, Tamara M.
description Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D2 R association rate and serotonin 5-HT2A antagonism, could contribute to this variation.
doi_str_mv 10.1177/0706743718777392
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6299187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0706743718777392</sage_id><sourcerecordid>2154565398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-1fe3155879b261edb81dd29f2371eea4c91f85252968525c2f29eb01f42765173</originalsourceid><addsrcrecordid>eNp1kV1vFCEUhonR2G313itD4o03o8AMA3hhslk_kzY1fsRLwjJnOjSzMAV2zfYv-KdlsrVqE7k5Cec5L7znRegJJS8oFeIlEaQVTS2oFELUit1DC9ooURFC-X20mNvV3D9CxyldknIYkw_REVOCS6XUAv08CzvYgM_4jUshdhATXqYUrDMZOvzd5QEvfXZT2tshZGfxGXTOmuyCx87jTxCmEQ7cFzu46zANEbwzr8oYPt9B3Dn4gUOPV8EO0XjAn2G-Stj4rohlUy29GffJpUfoQW_GBI9v6gn69u7t19WH6vT8_cfV8rSyTctyRXuoKedSqDVrKXRrSbuOqZ6VPQCYxiraS844U-1cLOuZgjWhfcNEy6moT9Drg-60XW-gs8V9NKOeotuYuNfBOP1vx7tBX4SdbplSZdVF4PmNQAxXW0hZb1yyMI7FXtgmzUjJQiouaUGf3UEvwzYWw4WivOEtr5UsFDlQNoaUIvS3n6FEz0nru0mXkad_m7gd-B1tAaoDkMwF_Hn1v4K_AEWisjE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2154565398</pqid></control><display><type>article</type><title>Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis</title><source>SAGE Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Martino, Davide ; Karnik, Vikram ; Osland, Sydney ; Barnes, Thomas R. E. ; Pringsheim, Tamara M.</creator><creatorcontrib>Martino, Davide ; Karnik, Vikram ; Osland, Sydney ; Barnes, Thomas R. E. ; Pringsheim, Tamara M.</creatorcontrib><description>Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D2 R association rate and serotonin 5-HT2A antagonism, could contribute to this variation.</description><identifier>ISSN: 0706-7437</identifier><identifier>EISSN: 1497-0015</identifier><identifier>DOI: 10.1177/0706743718777392</identifier><identifier>PMID: 29758999</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Antipsychotics ; In Review Series ; Meta-analysis ; Movement disorders ; Psychotropic drugs ; Schizophrenia ; Systematic review</subject><ispartof>Canadian journal of psychiatry, 2018-11, Vol.63 (11), p.730-739</ispartof><rights>The Author(s) 2018</rights><rights>The Author(s) 2018 2018 Canadian Psychiatric Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-1fe3155879b261edb81dd29f2371eea4c91f85252968525c2f29eb01f42765173</citedby><cites>FETCH-LOGICAL-c462t-1fe3155879b261edb81dd29f2371eea4c91f85252968525c2f29eb01f42765173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299187/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299187/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,21819,27922,27924,27925,43621,43622,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29758999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martino, Davide</creatorcontrib><creatorcontrib>Karnik, Vikram</creatorcontrib><creatorcontrib>Osland, Sydney</creatorcontrib><creatorcontrib>Barnes, Thomas R. E.</creatorcontrib><creatorcontrib>Pringsheim, Tamara M.</creatorcontrib><title>Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis</title><title>Canadian journal of psychiatry</title><addtitle>Can J Psychiatry</addtitle><description>Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D2 R association rate and serotonin 5-HT2A antagonism, could contribute to this variation.</description><subject>Antipsychotics</subject><subject>In Review Series</subject><subject>Meta-analysis</subject><subject>Movement disorders</subject><subject>Psychotropic drugs</subject><subject>Schizophrenia</subject><subject>Systematic review</subject><issn>0706-7437</issn><issn>1497-0015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kV1vFCEUhonR2G313itD4o03o8AMA3hhslk_kzY1fsRLwjJnOjSzMAV2zfYv-KdlsrVqE7k5Cec5L7znRegJJS8oFeIlEaQVTS2oFELUit1DC9ooURFC-X20mNvV3D9CxyldknIYkw_REVOCS6XUAv08CzvYgM_4jUshdhATXqYUrDMZOvzd5QEvfXZT2tshZGfxGXTOmuyCx87jTxCmEQ7cFzu46zANEbwzr8oYPt9B3Dn4gUOPV8EO0XjAn2G-Stj4rohlUy29GffJpUfoQW_GBI9v6gn69u7t19WH6vT8_cfV8rSyTctyRXuoKedSqDVrKXRrSbuOqZ6VPQCYxiraS844U-1cLOuZgjWhfcNEy6moT9Drg-60XW-gs8V9NKOeotuYuNfBOP1vx7tBX4SdbplSZdVF4PmNQAxXW0hZb1yyMI7FXtgmzUjJQiouaUGf3UEvwzYWw4WivOEtr5UsFDlQNoaUIvS3n6FEz0nru0mXkad_m7gd-B1tAaoDkMwF_Hn1v4K_AEWisjE</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Martino, Davide</creator><creator>Karnik, Vikram</creator><creator>Osland, Sydney</creator><creator>Barnes, Thomas R. E.</creator><creator>Pringsheim, Tamara M.</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181101</creationdate><title>Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis</title><author>Martino, Davide ; Karnik, Vikram ; Osland, Sydney ; Barnes, Thomas R. E. ; Pringsheim, Tamara M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-1fe3155879b261edb81dd29f2371eea4c91f85252968525c2f29eb01f42765173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antipsychotics</topic><topic>In Review Series</topic><topic>Meta-analysis</topic><topic>Movement disorders</topic><topic>Psychotropic drugs</topic><topic>Schizophrenia</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martino, Davide</creatorcontrib><creatorcontrib>Karnik, Vikram</creatorcontrib><creatorcontrib>Osland, Sydney</creatorcontrib><creatorcontrib>Barnes, Thomas R. E.</creatorcontrib><creatorcontrib>Pringsheim, Tamara M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martino, Davide</au><au>Karnik, Vikram</au><au>Osland, Sydney</au><au>Barnes, Thomas R. E.</au><au>Pringsheim, Tamara M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis</atitle><jtitle>Canadian journal of psychiatry</jtitle><addtitle>Can J Psychiatry</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>63</volume><issue>11</issue><spage>730</spage><epage>739</epage><pages>730-739</pages><issn>0706-7437</issn><eissn>1497-0015</eissn><abstract>Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D2 R association rate and serotonin 5-HT2A antagonism, could contribute to this variation.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>29758999</pmid><doi>10.1177/0706743718777392</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0706-7437
ispartof Canadian journal of psychiatry, 2018-11, Vol.63 (11), p.730-739
issn 0706-7437
1497-0015
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6299187
source SAGE Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Antipsychotics
In Review Series
Meta-analysis
Movement disorders
Psychotropic drugs
Schizophrenia
Systematic review
title Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A06%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Movement%20Disorders%20Associated%20With%20Antipsychotic%20Medication%20in%20People%20With%20Schizophrenia:%20An%20Overview%20of%20Cochrane%20Reviews%20and%20Meta-Analysis&rft.jtitle=Canadian%20journal%20of%20psychiatry&rft.au=Martino,%20Davide&rft.date=2018-11-01&rft.volume=63&rft.issue=11&rft.spage=730&rft.epage=739&rft.pages=730-739&rft.issn=0706-7437&rft.eissn=1497-0015&rft_id=info:doi/10.1177/0706743718777392&rft_dat=%3Cproquest_pubme%3E2154565398%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2154565398&rft_id=info:pmid/29758999&rft_sage_id=10.1177_0706743718777392&rfr_iscdi=true